folder

High-resolution molecular atlas of a lung tumor in 3D

Authors

  • T.M. Pentimalli
  • Simon Schallenberg
  • D. León-Periñán
  • I. Legnini
  • I. Theurillat
  • G. Thomas
  • A. Boltengagen
  • S. Fritzsche
  • J. Nimo
  • L. Ruff
  • G. Dernbach
  • P. Jurmeister
  • S. Murphy
  • M. Gregory
  • Y. Liang
  • M. Cordenonsi
  • S. Piccolo
  • F. Coscia
  • A. Woehler
  • N. Karaiskos
  • F. Klauschen
  • N. Rajewsky

Journal

  • bioRxiv

Citation

  • bioRxiv

Abstract

  • Cells live and interact in three-dimensional (3D) cellular neighborhoods. However, histology and spatial omics methods mostly focus on 2D tissue sections. Here we present a 3D spatial atlas of a routine clinical sample, an aggressive human lung carcinoma, by combining in situ quantification of 960 cancer-related genes across ~340,000 cells with measurements of tissue-mechanical components. 3D cellular neighborhoods subdivided the tumor microenvironment into tumor, stromal, and immune multicellular niches. Interestingly, pseudotime analysis suggested that pro-invasive epithelial-to-mesenchymal transition (EMT), detected in stroma-infiltrating tumor cells, already occurred in one region at the tumor surface. There, myofibroblasts and macrophages specifically co-localized with pre-invasive tumor cells and their multicellular molecular signature identified patients with shorter survival. Moreover, cytotoxic T-cells did not infiltrate this niche but colocalized with inhibitory dendritic and regulatory T cells. Importantly, systematic scoring of cell-cell interactions in 3D neighborhoods highlighted niche-specific signaling networks accompanying tumor invasion and immune escape. Compared to 2D, 3D neighborhoods improved the characterization of immune niches by identifying dendritic niches, capturing the 3D extension of T-cell niches and boosting the quantification of niche-specific cell-cell interactions, including druggable immune checkpoints. We believe that 3D communication analyses can improve the design of clinical studies investigating personalized, combination immuno-oncology therapies.


DOI

doi:10.1101/2023.05.10.539644